Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects

Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects

The overall approach to the treatment of multiple myeloma (MM) has undergone several changes during the past decade. and proteasome inhibitors (PIs) including bortezomib, carfilzomib, and ixazomib have considerably improved the outcomes in affected patients. The first-in-class selective PI bortezomi...

Full description

Bibliographic Details
Main Authors: Elia Pancheri, Valeria Guglielmi, Grzegorz M. Wilczynski, Manuela Malatesta, Paola Tonin, Giuliano Tomelleri, Dominika Nowis, Gaetano Vattemi
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
multiple myeloma
proteasome inhibitors
bortezomib
peripheral neuropathy
cardiotoxicity
muscle toxicity
Online Access:https://www.mdpi.com/2072-6694/12/9/2540

Internet

https://www.mdpi.com/2072-6694/12/9/2540

Similar Items